U.S. Antacids Market (2025 - 2030) Size, Share & Trends Analysis Report By Type (Tablet, Liquid, Others), By End-use (Retail Pharmacy, Hospital Pharmacy, Others), Key Companies, Competitive Analysis, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Type
                        1.2.2. End use
                        1.2.3. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Type outlook
                        2.2.2. End use outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Antacid Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                        3.2.2. Market restraint analysis
                    3.3. U.S. Antacid Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
                    3.4. U.S. Antacid Market: Pipeline Analysis
Chapter 4. U.S. Antacid Market: Type Estimates & Trend Analysis
                    4.1. Type Segment Dashboard
                    4.2. U.S. Antacid Market: Type Movement Analysis
                    4.3. U.S. Antacid Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
                    4.4. Tablet
                        4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    4.5. Liquid
                        4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    4.6. Others
                        4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Antacid Market: End use Estimates & Trend Analysis
                    5.1. End use Segment Dashboard
                    5.2. U.S. Antacid Market: End use Movement Analysis
                    5.3. U.S. Antacid Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
                    5.4. Hospital Pharmacy
                        5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.5. Retail Pharmacy
                        5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                    5.6. Others
                        5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
                    6.1. Recent Developments & Impact Analysis, By Key Market Participants
                    6.2. Company/Competition Categorization
                    6.3. Vendor Landscape
                        6.3.1. Key company heat map analysis, 2024
                    6.4. Company Profiles
                        6.4.1. Haleon Group of Companies.
                            6.4.1.1. Company overview
                            6.4.1.2. Financial performance
                            6.4.1.3. Type benchmarking
                            6.4.1.4. Strategic initiatives
                        6.4.2. Bayer AG
                            6.4.2.1. Company overview
                            6.4.2.2. Financial performance
                            6.4.2.3. Type benchmarking
                            6.4.2.4. Strategic initiatives
                        6.4.3. Boehringer Ingelheim International GmbH
                            6.4.3.1. Company overview
                            6.4.3.2. Financial performance
                            6.4.3.3. Type benchmarking
                            6.4.3.4. Strategic initiatives
                        6.4.4. Dr. Reddy’s Laboratories Ltd.
                            6.4.4.1. Company overview
                            6.4.4.2. Financial performance
                            6.4.4.3. Type benchmarking
                            6.4.4.4. Strategic initiatives
                        6.4.5. Sanofi
                            6.4.5.1. Company overview
                            6.4.5.2. Financial performance
                            6.4.5.3. Type benchmarking
                            6.4.5.4. Strategic initiatives
                        6.4.6. Reckitt Benckiser Group plc
                            6.4.6.1. Company overview
                            6.4.6.2. Financial performance
                            6.4.6.3. Type benchmarking
                            6.4.6.4. Strategic initiatives
                        6.4.7. Sun Pharmaceuticals Ltd.
                            6.4.7.1. Company overview
                            6.4.7.2. Financial performance
                            6.4.7.3. Type benchmarking
                            6.4.7.4. Strategic initiatives
                        6.4.8. Takeda Pharmaceutical Company Limited
                            6.4.8.1. Company overview
                            6.4.8.2. Financial performance
                            6.4.8.3. Type benchmarking
                            6.4.8.4. Strategic initiatives
                        6.4.9. Pfizer Inc.
                            6.4.9.1. Company overview
                            6.4.9.2. Financial performance
                            6.4.9.3. Type benchmarking
                            6.4.9.4. Strategic initiatives
                        6.4.10. Procter & Gamble
                            6.4.10.1. Company overview
                            6.4.10.2. Financial performance
                            6.4.10.3. Type benchmarking
                            6.4.10.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. antacid market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. antacid market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. antacid market: market outlook
Fig. 10 U.S. antacid competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. antacid market driver impact
Fig. 16 U.S. antacid market restraint impact
Fig. 17 U.S. antacid market strategic initiatives analysis
Fig. 18 U.S. antacid market: Type movement analysis
Fig. 19 U.S. antacid market: Type outlook and key takeaways
Fig. 20 Tablet market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Liquid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 U.S. antacid Market: End use movement Analysis
Fig. 24 U.S. antacid market: End use outlook and key takeaways
Fig. 25 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Retail pharmacy market estimates and forecasts,2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecasts,2018 - 2030 (USD Million)